Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1500-pRCC,Adv, Sunitinib vs MET inhib | 1 | Y | 1 Sunitinib | 180 | 27 | 13 | 7 | 3 | 1 | 0 | 07/25/2016 | 210 | 88 |
| 2 Cabozantinib | 27 | 15 | 9 | 4 | 0 | 0 | ||||||||
| 3 Crizotinib | 28 | 15 | 8 | 4 | 0 | 0 | ||||||||
| 4 Savolitinib | 29 | 16 | 10 | 4 | 2 | 0 | ||||||||
| 111 | 59 | 34 | 15 | 3 | 0 | |||||||||
| S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 1 | Y | 1 TICE BCG | 969 | 59 | 45 | 27 | 19 | 4 | 1 | 02/24/2017 | 151 | 63 | |
| 2 Tokyo-172 BCG | 57 | 44 | 27 | 16 | 4 | 0 | ||||||||
| 3 Prime + Tokyo-172 BCG | 55 | 43 | 26 | 14 | 3 | 1 | ||||||||
| 171 | 132 | 80 | 49 | 11 | 2 | |||||||||
| S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab | 1 | Y | 1 Atezolizumab | 148 | 84 | 69 | 43 | 27 | 6 | 1 | 03/13/2017 | 204 | 93 | |
| 84 | 69 | 43 | 27 | 6 | 1 | |||||||||
| S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | 1 | Y | 0 Induction SST | 1273 | 7 | 7 | 7 | 7 | 7 | 0 | 09/24/2018 | 48 | 22 | |
| 7 | 7 | 7 | 7 | 7 | 0 | |||||||||
| 2 | Y | 1 Standard Systemic Therapy Only | 1273 | 1 | 1 | 1 | 1 | 1 | 0 | 09/24/2018 | ||||
| 2 SST + Surgery/RT | 1 | 1 | 1 | 1 | 1 | 0 | ||||||||
| 2 | 2 | 2 | 2 | 2 | 0 | |||||||||
| Yes | A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 1 | E | Total Registrations | 4 | 2 | 1 | 1 | 1 | 0 | 11/23/2016 | 56 | 34 | |
| 4 | 2 | 1 | 1 | 1 | 0 | |||||||||
| EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) | 0 | E | Total Registrations | 22 | 19 | 8 | 4 | 1 | 0 | 09/29/2017 | 309 | 140 | ||
| 22 | 19 | 8 | 4 | 1 | 0 | |||||||||
| 1 | E | Total Registrations | 17 | 14 | 6 | 3 | 1 | 0 | 09/29/2017 | |||||
| 17 | 14 | 6 | 3 | 1 | 0 | |||||||||
| NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel | 1 | E | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 08/24/2017 | 232 | 118 | ||
| 1 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 08/24/2017 | |||||
| 1 | 0 | 0 | 0 | 0 | 0 | |||||||||
| No | A031501-Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs | 0 | E | Total Registrations | 9 | 9 | 9 | 1 | 0 | 0 | 05/03/2018 | 212 | 110 | |
| 9 | 9 | 9 | 1 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 9 | 9 | 9 | 3 | 0 | 0 | 05/03/2018 | |||||
| 9 | 9 | 9 | 3 | 0 | 0 | |||||||||
| EA8153-Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) | 1 | E | Total Registrations | 2 | 2 | 2 | 2 | 0 | 0 | 08/08/2018 | 42 | 8 | ||
| 2 | 2 | 2 | 2 | 0 | 0 | |||||||||
| R0924-Pros, NADT+WPRT vs. NADT+P&SV RT | 1 | E | Total Registrations | 88 | 33 | 16 | 3 | 1 | 0 | 11/25/2013 | 366 | 164 | ||
| 88 | 33 | 16 | 3 | 1 | 0 | |||||||||